学术引领微生态，锐翌生物携全链条成果亮相2025第三届肠道微生态与肠菌移植论坛！

Group 1 - The third Gut Microecology and Fecal Microbiota Transplantation Academic Forum was held in Suzhou, attracting hundreds of top experts and scholars, with online participation reaching 90,000 [1] - The microecology industry is recognized as a strategic new track for global competition and is becoming a core force in empowering life and health development, supported by multiple national policies and research plans in China [3] - The forum showcased the latest research results, clinical practices, and industry insights in the field of gut microecology and FMT, highlighting the innovative vitality and development potential of the microecology medical field [4] Group 2 - The forum included the signing ceremony of the National Clinical Medical Research Center for Digestive Diseases (Shanghai) sub-center, enhancing regional medical resource collaboration [5] - The release of expert consensus documents on the standardized clinical application of gut microbiome testing and adult FMT management provides unified guidelines for clinical diagnosis and treatment [6] - The forum emphasized the systematic construction of FMT, aiming to lead a new era of microecological diagnosis and treatment for chronic diseases [6] Group 3 - Professor Qin Huanlong presented a report on the systematic construction of FMT, detailing its development achievements and future directions, emphasizing FMT as a revolutionary green therapy for major chronic diseases [8] - The report highlighted the need for a comprehensive system to enhance the safety, effectiveness, and scientific level of FMT through clinical application and technological control [8] - The forum discussed breakthroughs in microbiome research related to FMT, addressing key questions about safety, scientific validity, and effectiveness [9] Group 4 - Dr. Qin Nan presented the latest advancements in gut microecology research and clinical applications, focusing on the full-chain solution from precise detection to intervention [10][11] - The company, Ruiyi Biotechnology, is recognized as a national-level specialized and innovative "little giant" enterprise, providing integrated solutions in the human microecology field [13] - The company has achieved significant academic recognition, including the Shanghai Science and Technology Progress Award for its project on gut microbiome disease classification [14] Group 5 - Ruiyi Biotechnology has obtained over 230 patents and software copyrights, demonstrating its leading position in technological independence [17] - The company has published over 60 papers in prestigious international journals, contributing to the academic discourse in the field [20] - In collaboration with Tongji University, Ruiyi's AI matching research for multi-disease donors and recipients was published in the top journal "Cell Host & Microbe," marking its international advancement in FMT research [22] Group 6 - The company has established a robust technical foundation through 16 years of clinical research and a database of 114,000 samples, linking 18 chronic diseases to gut microbiota [23] - Ruiyi has developed an AI-based donor-recipient matching model to improve the success rate of FMT, validated through clinical practice [24] - The company has created a standardized preparation system for FMT, ensuring safety and efficacy through rigorous quality control measures [27] Group 7 - The forum showcased Ruiyi's core product matrix, which emphasizes precision, efficiency, and strong clinical adaptability, attracting interest from experts and institutional partners [29] - The one-stop FMT platform aims to reconstruct a functional gut microecological system to treat or assist in treating gut-related diseases [33] - The company continues to push for the transformation of research into clinical applications, contributing to the standardized development of microecology medicine [38]